东京, Sept. 25, 2025 (GLOBE NEWSWIRE) -- 医疗保健必须被视为全球对安全、繁荣和韧性的最具战略意义的投资，而不是一种财务负担——沙特王室顾问兼 King Faisal Specialist Hospital and Research Centre (KFSHRC) 首席执行官 Majid Alfayyadh 博士阁下在其 C3 Davos of Healthcare™ 东京峰会的演讲中声明。 Alfayyadh 博士强调，对医疗保健系统的投资将直接影响到可以被拯救的生命、推动经济、创造岗位、带来更强的全球竞争力，同时让各国能够承受得住未来的危机，包括大流行病、气候相关的紧急健康问题以及自然灾害。 他特别强调了健康挑战在全球范围内的趋同性——癌症、糖尿病和心血管疾病等慢性病的日益增多；气候变化造成媒介传播疾病加速扩散；低、中收入国家的不平等差距加剧；以及新冠疫情暴露出来的弱点——这些都是各国必须将医疗卫生重新定义为集体安全投资的紧迫原因。 为了在全球范围内打造可持续的医疗健康系统，他提出了五个关键的投资领域：现代医院基础设施，包括急诊和重症监护能力；数字健康以及 AI 驱动的平 ...

海南产经新观察：乐城先行区，从"政策试验田"到"产业新高地" 中新网海南琼海9月25日电 (记者 张茜翼)2025海南·国际创新药械 "三医协同"可信数据空间共建发布会 近日在海南博鳌乐城国际医疗旅游先行区(简称"乐城先行区")举行，助力乐城先行区加快构建产业新高 地。 图为2025海南·国际创新药械"三医协同"可信数据空间共建发布会举行。 (乐城先行区管理局 供 图) 海南省国际创新药械"三医协同"可信数据空间，已成功获批国家数据局2025年行业可信数据空间创新发 展试点，是全国卫生领域唯一获批的行业可信数据空间试点。该空间将通过技术和运营模式的创新，推 动数据资源交互、建立共识规则，实现多方主体价值共享，解决医疗数据"供不出、流不动、用不好"的 行业共性痛点问题。 琼海市委书记、乐城先行区管理局党委书记周长强表示，海南省国际创新药械"三医协同"可信数据空间 将重点突破医疗数据流通应用的技术痛点和制度问题，进一步提升真实世界数据的完整性与应用价值； 未来乐城先行区将以制度创新为核心，全力打造数字健康领域标杆项目，推动创新药械研发与多中心临 床研究合作，加快构建国际医疗旅游高地。 乐城先行区2013年获准设立 ...

摘要 中国在全球创新生态中扮演的角色日益重要，尤其自 2022 年 ADC 药物 兴起后，预计中国原创资产在美国 FDA 获批药物中的渗透率将从 5%增 至 2024 年的 35%，贡献年度 220 亿美元的海外收入。 中国医药企业面临超过 1,000 亿美元的专利悬崖或收入缺口，主要集中 在肿瘤学、免疫学和心脏代谢疾病领域，中国企业正通过增加全球临床 试验份额来填补这一缺口。 海外投资者对中国医药行业持谨慎态度，关注估值和地缘政治风险，对 中国与西方公司之间的估值差距以及潜在的地缘政治波动寻求更多保障。 美国投资者对 China Innovation Ban 及欧盟相关条款的执行性担忧较 少，但相较于亚洲投资者，他们更关注地缘政治和估值问题，认为当前 估值差距未完全反映长期全球化收益。 海外生物制药公司对中国临床数据的信心增强，通过购买中国资产获得 高质量的临床前、临床过程和病人数据，推动中国资产受到更多关注。 数字医疗板块表现突出，受益于医院处方外流、集采后原研药出流以及 线下药房线上化，京东健康和阿里健康等公司通过战略合作进一步推动 业务增长。 中国 CRO 公司通过外部授权和客户合作，在创新资产出海过 ...

Core Viewpoint - The strategic collaboration between Philips and Masimo in patient monitoring signifies a shift towards integrated solutions in the medical device industry, highlighting the importance of partnerships to meet clinical demands for comprehensive healthcare solutions [1][6]. Collaboration Content and Focus - Philips and Masimo will deepen their collaboration through technology integration, focusing on enhancing patient monitoring capabilities [2]. - The partnership aims to develop next-generation patient monitoring solutions that address the clinical needs for mobility, wearability, and intelligence, incorporating AI algorithms for improved patient outcomes [5]. Product Features and Collaborative Foundations - Philips has a strong presence in multi-parameter patient monitoring devices, particularly in high-acuity settings, while Masimo specializes in non-invasive sensors and innovative monitoring parameters [4]. - Key technologies include Masimo's SET pulse oximetry technology and Radius PPG wearable sensors, which will be integrated into Philips' monitoring systems [4][5]. Insights for Domestic Manufacturers - Domestic companies often excel in specific innovations but may struggle to scale without partnerships with larger firms. Finding complementary partners to embed innovations into comprehensive solutions is crucial for growth [9]. - Mindray serves as a representative example of a domestic firm that integrates sensors, algorithms, and monitoring platforms internally, adopting a "full-stack self-research" model [9]. Areas Suitable for Collaboration - The medical device industry is moving towards systematic strategies for collaboration, emphasizing the need for integrated solutions rather than isolated innovations [6][10]. - Collaborations can enhance market efficiency, shorten the path from R&D to market, and facilitate access to reimbursement and regulatory approvals [10]. Areas Unsuitable for Collaboration - Direct competition in core devices, such as ventilators and surgical robots, may hinder collaboration due to potential dilution of competitive advantages [11]. - Areas with severe product homogeneity or conflicting business models may also present challenges for effective partnerships [11]. Future Observations - The trend of collaboration among multinational companies to quickly address market gaps may influence domestic firms to consider open partnerships in emerging fields like AI and wearable sensors [12].

Group 1 - The company, Ark Health (06086), has observed a recent increase in its share price on the Hong Kong Stock Exchange as of September 12, 2025 [1] - The company announced its proprietary "Xing Shi" large model, which serves as the foundation for five flagship applications aimed at enhancing clinical diagnostic support and personalized chronic disease management [1] - A strategic partnership has been established with Innovent Biologics to integrate Ark's H2H digital health ecosystem with Innovent's weight management therapy pipeline, utilizing the "Xing Shi" model for personalized digital maintenance and compliance support in China's growing weight management market [1] - The company has also formed a strategic collaboration with Zhejiang Otsuka Pharmaceutical Co., Ltd. to develop comprehensive digital solutions that combine AI technology with Otsuka's innovative drug portfolio, focusing on drug support services, targeted patient outreach programs, and health education initiatives [1] Group 2 - The board confirmed that the information contained in the press release does not constitute insider information as defined under the relevant listing rules and securities regulations [2] - The board is not aware of any reasons for the increase in share price or any information that would require disclosure to prevent a false market in the shares [2]

Group 1 - The core viewpoint emphasizes that green transformation and digital health are the most promising areas for future China-South Korea cooperation [1] - The 25th China International Investment and Trade Fair attracted representatives from various countries, highlighting China's improved business environment and cooperation potential in green low-carbon, new energy, and healthcare sectors [1][3] - The foreign investment law and the reduction of the "negative list" are seen as key factors enhancing foreign investor confidence and market access [2] Group 2 - The healthcare sector is experiencing increased interest from multinational companies, with China viewed as a "cooperation high ground" due to its large market and capital advantages [3][5] - The recent policy innovations in China, particularly the "7+6" policy in the Beidaihe New Area, have significantly lowered the entry barriers for foreign medical enterprises [5][6] - The global push for carbon neutrality is driving international capital into China's green energy sector, with companies like Hyper Wind recognizing China's leadership in wind energy technology [7] Group 3 - The rapid development of artificial intelligence and big data in China is creating vast market opportunities for innovative companies, particularly in the field of smart transportation and carbon reduction [9] - There is a noticeable shift in foreign companies' strategies towards localized innovation in China, with South Korean battery companies increasing investments to customize products for the Chinese market [10] - The overall sentiment among international representatives is that China's large market size, improving institutional environment, and vibrant innovation ecosystem are key drivers for foreign investment [10]

Core Insights - Health 160 International Limited has successfully passed the listing hearing on the Hong Kong Stock Exchange, marking a significant milestone for the digital health sector in China [1] - The company, established in 2005, is one of the early entrants in the "Internet + Healthcare" space, offering a comprehensive service system that includes appointment booking, online consultations, health management, pharmaceutical e-commerce, and medical information technology [1] - Health 160 has connected with over a thousand large hospitals nationwide, boasting over 100 million registered users and an average daily service volume of one million, showcasing its competitive advantage in digital healthcare services [1] Company Plans - The successful listing hearing is a validation of Health 160's business model and growth prospects, providing strong capital support for future expansion [1] - The company plans to use the raised funds for technology research and development, market expansion, and strategic investments, particularly in AI-assisted diagnosis, chronic disease management, and smart hospital solutions [1] Industry Impact - Analysts suggest that Health 160's listing will accelerate the consolidation of the digital health industry, directing more resources towards leading platforms and enhancing the accessibility and efficiency of public health services [1]

Group 1 - The Zhejiang Province has officially launched the construction of a national artificial intelligence application pilot base focused on intelligent specialist doctors in the medical field [1] - The project aims to leverage Zhejiang's technological advantages in large models, humanoid robots, and intelligent computing to provide common solutions for the healthcare industry [1] - The base will create a pilot verification platform that includes computing power support, data support, model research and development, verification testing, and achievement transformation [1] Group 2 - In 2023, the Zhejiang Provincial Health Commission, in collaboration with Ant Group, developed the first digital health service platform in the country, integrating over 30 intelligent health services [1] - This platform has connected more than 400 healthcare institutions in the province and served over 60 million people, saving an average of 20 minutes for patients seeking medical care [1] - The initiative has been recognized as one of the top ten new measures for promoting medical reform and improving public health in 2024 [1] Group 3 - Ant Group's Vice President and General Manager of the Medical Health Division, Zhang Junjie, stated that the company will continue to open platform technology and collaborate with ecosystem partners to support the construction of the national AI medical application base [1] - The goal is to make AI accessible to more people's health and ensure that everyone has a reliable health management system [1]

Core Points - The Yuhang District Public Health Center has officially opened, marking a significant advancement in the district's public health services [1][2] - The center spans a total area of 34,700 square meters and integrates seven key functions including disease prevention, health monitoring, emergency response, and health education [1][2] - The health science popularization museum on the first floor is expected to become a new hub for health education, featuring interactive exhibits and VR systems [1][2] Summary by Sections - **Public Health Center Features** - The center includes the district's disease control center, emergency medical services, and a public health emergency command center [1][2] - The second floor houses a fully digital emergency command center that utilizes the Yuhang District Emergency Intelligence Control Platform for monitoring and decision-making [2] - The center also features a high-standard health testing laboratory and a 120 dispatch center for emergency calls [2] - **Integration and Coordination** - The establishment of the center aims to consolidate previously scattered public health resources, enhancing coordination and resource sharing [2] - The upgraded 120 dispatch center and health supervision services are designed to provide more robust health protection for residents [2] - **Future Plans** - The district plans to strengthen its modern disease prevention and control system and improve pre-hospital emergency services [2] - The health science popularization museum will serve as a regular health education base to enhance residents' health literacy [2]

Group 1 - Granite Asia, a leading global venture capital firm based in Singapore, announced the appointment of three new managing partners [2] - Ming Eng will lead Granite Asia's private credit strategy and has a background in investment banking with experience at Goldman Sachs and Macquarie [4] - Haojun Li focuses on equity investments in consumer technology and AI applications, having previously worked at Tencent and Vertex China [5][7] - Joshua Wu specializes in investments in enterprise services, AI applications, and digital health, with prior experience at Alibaba and Tencent [9]